A promising new medication for weight loss
With dramatically increasing rates of obesity across the United States and the world, obesity is a serious disease that calls for greater intervention and accessible treatments. Mounjaro, also known as Tirzepatide, a brand new medication approved by the FDA in May 2022, rises to the occasion. Although currently indicated for use in patients with type 2 diabetes, it shows incredible weight loss results independent of the diagnosis of diabetes.
Studies show that about 9 out of 10 individuals with obesity lost weight while taking Mounjaro. In fact, it outperforms some of the existing weight loss medications that we have on the market. Results from a recent study show that Mounjaro, at the highest dose, may actually work as well as bariatric surgery!
Mounjaro, like Wegovy(semaglutide) and Ozempic, is a once a week injectable medication. It is unique however, in that it targets two hormones, called GIP and GLP1 (Wegovy and Ozempic target just GLP1).
Both of these hormones are involved in maintaining healthy blood sugar levels as well as controlling hunger and cravings.
We know that the disease of obesity will not go away on its own. It is a chronic disease that requires medical intervention. We need to make the most of every tool we have in our toolbox to combat it. As a board-certified obesity medicine specialist, I think that Mounjaro may be a game-changer for the treatment of obesity.
Mounjaro, as well as all the other prescription weight loss medications, are used safely and effectively during both the weight loss phase and the maintenance phase to help keep the weight off.
Call us to set up a consultation and we are happy to answer any questions you may have about Mounjaro or any of the other prescription weight loss medications.